Alector Revenue and Competitors

Location

$194.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Alector's estimated annual revenue is currently $197.9M per year.(i)
  • Alector received $133.0M in venture funding in July 2018.
  • Alector's estimated revenue per employee is $744,135
  • Alector's total funding is $194.5M.
  • Alector's current valuation is $1.4B. (January 2022)

Employee Data

  • Alector has 266 Employees.(i)
  • Alector grew their employee count by -11% last year.

Alector's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
VP Clinical Development OncologyReveal Email/Phone
3
VP, Biometrics & Digital ScienceReveal Email/Phone
4
SVP, Head Clinical Development, NeurologyReveal Email/Phone
5
VP, Technical Operations & Supply ChainReveal Email/Phone
6
VP, Clinical Development OperationsReveal Email/Phone
7
VP, Healthcare Legal and ComplianceReveal Email/Phone
8
SVP, Portfolio, Program and Alliance ManagementReveal Email/Phone
9
VP, Technology and Digital HealthReveal Email/Phone
10
ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M30-29%N/AN/A
Add Company

What Is Alector?

We are ambitious. We are curious. We are pioneers. At Alector we are forging a new path for overcoming the tremendous burden caused by neurodegenerative diseases and cancer. Our approach centers on mining the human genome to identify mutations in immune system genes that increase the risk for these disorders. From there, we are innovating new drugs that counteract the damage these mutations cause. Alector is a privately-owned biotechnology based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

keywords:Biotechnology,Finance,Healthcare,Pharmaceuticals

$194.5M

Total Funding

266

Number of Employees

$197.9M

Revenue (est)

-11%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Alector News

2022-04-19 - Alector, Inc. (NASDAQ:ALEC) Receives Average Rating of ...

Shares of Alector, Inc. (NASDAQ:ALEC – Get Rating) have earned a consensus rating of “Buy” from the eight brokerages that are presently...

2022-04-17 - Alector: Expect Phase 3 Data Next Year

Alector has a novel approach to neurodegenerative diseases. Alector thinks that the immune system gone wrong causes those diseases.

2022-03-30 - Alector Announces Appointment of Gary Romano, MD, Ph.D.,

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of...

2019-09-03 - Alector to Present at 17th Annual Morgan Stanley Global ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$29.7M2707%N/A
#2
$10.1M300-13%N/A
#3
$69M31819%$743M
#4
$71.8M3315%$306M
#5
$127.9M37910%N/A

Alector Funding

DateAmountRoundLead InvestorsReference
2013-11-01$UndisclosedAPolaris Venture PartnersArticle
2015-09-17$32.3MCMultipleArticle
2016-01-08$29.5MDDementia Discovery FunArticle
2018-07-26$133.0MEMultipleArticle